VEGFA and glioblastoma: While the monoclonal VEGF-antibody bevacizumab was approved for recurrent glioblastoma in some countries based on prolonged PFS and clinical benefit, such as the reduction of steroid need and neurological symptoms, it did not prolong OS in several phase 3 clinical trials - both in newly diagnosed and recurrent disease [3, 4, 11, 14].